We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Windtree Therapeutics Inc (WINT) USD0.001

Sell:$0.25 Buy:$0.26 Change: $0.003 (1.19%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$0.25
Buy:$0.26
Change: $0.003 (1.19%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$0.25
Buy:$0.26
Change: $0.003 (1.19%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.

Contact details

Address:
2600 Kelly Rd Ste 100
WARRINGTON
18976-3652
United States
Telephone:
+1 (215) 4889300
Website:
https://windtreetx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
WINT
ISIN:
US97382D5014
Market cap:
$2.79 million
Shares in issue:
11.05 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Craig Fraser
    Chairman of the Board
  • Jed Latkin
    President, Chief Executive Officer, Director
  • Jamie Mcandrew
    Chief Financial Officer, Senior Vice President, Principal Accounting Officer
  • Eric Curtis
    Chief Operating Officer, Senior Vice President
  • Diane Carman
    Senior Vice President, General Counsel, Corporate Secretary
  • Steven Simonson
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.